Literature DB >> 2024815

Complement is activated in the upper respiratory tract during influenza virus infection.

A B Bjornson1, M A Mellencamp, G M Schiff.   

Abstract

The purpose of this pilot study was to determine whether complement is activated in the upper respiratory tract during experimental influenza virus infection in human volunteers. Seven subjects were challenged with influenza A/Bethesda/1/85 (H3N2), and four subjects received placebo. C3a and C5a concentrations were measured by radioimmunoassay in nasal lavage fluids before challenge and for 8 days after challenge. A significant increase (p less than 0.05) in C3a and C5a concentrations was demonstrated in lavage fluids from subjects who developed influenza illness as compared with uninfected control subjects and infected subjects who remained asymptomatic. Maximal levels of C3a and C5a were detected during the recovery phase of illness. These results suggest that complement is activated in the airway in response to influenza illness.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024815     DOI: 10.1164/ajrccm/143.5_Pt_1.1062

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  28 in total

Review 1.  Why do viruses make infants wheeze?

Authors:  I M Balfour-Lynn
Journal:  Arch Dis Child       Date:  1996-03       Impact factor: 3.791

2.  Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line.

Authors:  S Varsano; M Kaminsky; M Kaiser; L Rashkovsky
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

3.  ArcA-regulated glycosyltransferase lic2B promotes complement evasion and pathogenesis of nontypeable Haemophilus influenzae.

Authors:  Sandy M S Wong; Frank St Michael; Andrew Cox; Sanjay Ram; Brian J Akerley
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

4.  Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response.

Authors:  Tao Peng; Liming Hao; Joseph A Madri; Xiao Su; Jack A Elias; Gregory L Stahl; Stephen Squinto; Yi Wang
Journal:  J Clin Invest       Date:  2005-05-12       Impact factor: 14.808

Review 5.  Influenza A virus infection kinetics: quantitative data and models.

Authors:  Amber M Smith; Alan S Perelson
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

6.  Gene expression signature-based screening identifies new broadly effective influenza a antivirals.

Authors:  Laurence Josset; Julien Textoris; Béatrice Loriod; Olivier Ferraris; Vincent Moules; Bruno Lina; Catherine N'guyen; Jean-Jacques Diaz; Manuel Rosa-Calatrava
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

7.  Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets.

Authors:  Cheryl M Cameron; Mark J Cameron; Jesus F Bermejo-Martin; Longsi Ran; Luoling Xu; Patricia V Turner; Ran Ran; Ali Danesh; Yuan Fang; Pak-Kei M Chan; Nutan Mytle; Timothy J Sullivan; Tassie L Collins; Michael G Johnson; Julio C Medina; Thomas Rowe; David J Kelvin
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

Review 8.  Does influenza transmission occur from asymptomatic infection or prior to symptom onset?

Authors:  Eleni Patrozou; Leonard A Mermel
Journal:  Public Health Rep       Date:  2009 Mar-Apr       Impact factor: 2.792

9.  Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

Authors:  Sam D Sanderson; Marilyn L Thoman; Kornelia Kis; Elizabeth L Virts; Edgar B Herrera; Stephanie Widmann; Homero Sepulveda; Joy A Phillips
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

10.  Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury.

Authors:  Cristiana C Garcia; Wynne Weston-Davies; Remo C Russo; Luciana P Tavares; Milene A Rachid; José C Alves-Filho; Alexandre V Machado; Bernhard Ryffel; Miles A Nunn; Mauro M Teixeira
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.